Copyright
©The Author(s) 2023.
World J Diabetes. Jun 15, 2023; 14(6): 741-757
Published online Jun 15, 2023. doi: 10.4239/wjd.v14.i6.741
Published online Jun 15, 2023. doi: 10.4239/wjd.v14.i6.741
Management strategy | Therapeutic approach | Description | Contraindications/issues |
Pharmacological | Anti-convulsants: Gabapentin; pregabalin | First line medication for painful DN[4,51]; gold standard for pain management[50,51] | Reports on misuse and increased death rate in patients[54] |
SSRI and SNRIs: Duloxetine; venlafaxine | First- and second-line therapy for painful DN[56,57] | Low evidence on venlafaxine effectiveness for painful DN treatment[58] | |
TCAs: Amitriptyline; desapramine | First and second-line therapy for painful DN | Associated with constipation, dry mouth, sleep disturbance, sexual dysfunction, somnolence, headaches, arrhythmias, constipation, sleep disturbances, and postural hypotension[4,63] | |
Opioids: Tramadol; trapentadol | Opted as acute salvage treatment or as a part of drug combination for painful DN treatment | Strong opioids are frequently associated with therapeutic abuse and misuse[68]; use of tramadol is more preferred due to reduced risk of abuse or misuse[68] | |
Sympathetic blocking agents (α-adrenergic antagonists): Clonidine; regitine; phenoxybenzamine | One of the opted therapies for complex regional pain syndrome treatment[72] | Limited evidence in RCT testing the drug’s efficacy in painful DN patients; efficiency of clonidine depends on relative functionality of nociceptors in painful DN patients, however no statistical significance is achieved although the trends of efficacy is shown[70] | |
Non-pharmacological | Sympathetic nerves blockade: Lumbar sympathetic nerves blockade; combined strategies of lumbar sympathetic pulsed radiofrequency and continuous epidural infusion; combined treatment of continuous sympathetic block and neurolysis with alcohol | Recommended for severe painful DN patients who failed to any pharmacological treatments | Patients demonstrated improved life expectancy, greater DN symptom improvement, satisfactory safety, rapid recovery, and rapid relief of pain[73-76]; associated with several limitations of additional diagnostic tools, small size population, short period of follow-up, and issue regarding combined treatment duration[75,76] |
Capsaicin | Recommended for patients with intolerable oral therapeutic consumption[4] | Low to moderate level of evidence for topical capsaicin efficacy[82,83]; associated with small nerve fibers injury and disturbed nociceptive signaling[84] | |
Neuromodulation devices: FREMS; SCS, NMES; TENS | Studies on their efficacy in painful DN is still on-going | Not yet approved for clinical guidelines for painful DN treatment due to very low evidence of efficacy[4,85,86] | |
Nutraceuticals: ALA; ALC; vitamin B12 | ALA improves numbness and paraesthesia with reduced side effects[89]; vitamin B12 is recommended to T2DM patients with metformin prescription[90] | There is a lack of standardization in quality and manufacturing of nutraceuticals[91,92]; low safety level due to less evidence of high-quality studies[87,93] |
- Citation: Ismail CAN. Issues and challenges in diabetic neuropathy management: A narrative review. World J Diabetes 2023; 14(6): 741-757
- URL: https://www.wjgnet.com/1948-9358/full/v14/i6/741.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i6.741